Both mucosal-associated invariant and natural killer T cell deficiency in multiple myeloma can be countered by PD-1 inhibition

Mérédis Favreau, Koen Venken, Sylvia Faict, Ken Maes, Kim De Veirman, Elke De Bruyne, Xavier Leleu, Louis Boon, Dirk Elewaut, Karin Vanderkerken, and Eline Menu

Disclosures: This work was financially supported by Kom op tegen kanker (KotK) and Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO-Vl). E.M. is a post-doctoral fellow supported by the AXA Research Foundation. K. Venken, K.M., K.D.V., E.D.B. are post-doctoral fellows of FWO-Vl. S.F. is a doctoral fellow supported by FWO-Vl. D.E. is supported by FWO-Vl and the Research Council of Ghent University. D.E. is also a member of a multidisciplinary research platform (MRP) of Ghent University and is supported by Interuniversity Attraction Pole (IUAP) grant Devrepair from the Belspo Agency (project P7/07).

Contributions: M.F., K. Venken, E.M., K. Vanderkerken and D.E. conceived and designed the research and wrote the manuscript; M.F. performed the experiment and analysed the data; E.M., K. Venken helped with the experiments. S.F., X.L. provided human samples. L.B. provided the murine anti-PD-1 antibody. E.M., K. Vanderkerken, K. Venken, L.B., D.E., K.M., S.F., K.D.V. and E.D.B. provided crucial suggestions and revised the manuscript.